ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous ...
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its ...
GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michigan iv ...
The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel ...
Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that ...
Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib ...
After years of quiet maturation, new approach methodologies and emerging clinical success for cell therapies are fueling ...
New mechanistic research and clinician-reported real-world experience adds to the evolving evidence base for birch ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Stealth AXiS™ surgical system ...
Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results